Dhan Chand

106 posts

Dhan Chand

Dhan Chand

@dhanschand

Scientist

Katılım Haziran 2013
331 Takip Edilen167 Takipçiler
Dhan Chand retweetledi
Pashtoon Kasi MD, MS
Pashtoon Kasi MD, MS@pashtoonkasi·
Nothing against radiation☢️but if we can have #immunotherapy like BOT/BAL eradicate/cure cancer, we can set a similar paradigm for our patients with MSS🔵 #ColorectalCancer as is now the case for patients with MSI-High🔴 tumors and spare additional toxicity. Now @cityofhope 👇🏽🙌🏽
Pashtoon Kasi MD, MS tweet media
Dr. Marwan G. Fakih@mgfakih

Study Details | FOLFOX, Botensilimab, and Balstilimab for the Treatment of Localized Rectal Cancer Before Surgery | ClinicalTrials.gov NCT06780787 RT-Sparing Neoadj pRectal Ca - FOLFOX + Botenislimab + Balstilimab-- 🙏Gateway Foundation for funding- now at City of Hope!

English
8
8
38
6.5K
Dhan Chand retweetledi
Jennifer Buell
Jennifer Buell@jbuell01·
When the “coldest” tumors melt: @MyriamChalabi breaks new ground (again) at #AACR25. NEOASIS Trial: • 80% MPR in dMMR (70% pCR!) • 60% MPR in pMMR BOT/BAL are pushing ICB into non-immunogenic tumors. #CancerImmunotherapy #BOT/BAL
Jennifer Buell tweet mediaJennifer Buell tweet mediaJennifer Buell tweet mediaJennifer Buell tweet media
English
1
33
102
36.4K
Dhan Chand retweetledi
Amalya Sargsyan
Amalya Sargsyan@amalsargsyan·
What a shift! In 2021, I was among people who loved reading @CancerWorldmag , now I authored the COVER story! 🤩 Huge honor and Motivation to Dream Big! Discussing Role Of IOs - BOT + BAL & the impact beyond data in MSS colon cancer. Check it out ⬇️ cancerworld.net/botensilimab-a…
Amalya Sargsyan tweet media
English
7
2
63
3K
Dhan Chand retweetledi
Dr. Marwan G. Fakih
Dr. Marwan G. Fakih@mgfakih·
GI/ASCO: We presented our Phase 1 BOT/BAL with FOLFOX in MSS MCRC. 14 patients on the phase 1 study. 10 had prior Ox and 12 had prior chemo, yet ORR was 10/14 patients (majority of the pts had liver mets). The combination was safe with 2 doses of BOT + Q2w FOLFOXBEV/BAT
Dr. Marwan G. Fakih tweet media
English
5
14
74
13.7K
Dhan Chand retweetledi
A.n.n.
A.n.n.@fireflyann·
ASCO #GI25 The future of immunotherapy in MSS colon cancer is here! UNICORN trial results Preoperative botensilimab (BOT) w or w/o balstilimab (BAL) for patients w/ resectable locally advanced pMMR or dMMR colon cancer: NCT05845450 PI: @FilippoPietran4 meetings.asco.org/abstracts-pres…
A.n.n. tweet media
English
1
24
74
4.4K
Dhan Chand retweetledi
Pashtoon Kasi MD, MS
Pashtoon Kasi MD, MS@pashtoonkasi·
🆕#GI25 abstracts now released! 📰 🗞️ Neoadjuvant #immunotherapy continues to impress! Building upon the paradigm shift of immunotherapy to earlier settings ➡️📈CURES🙌🏽 ✅NEST🪺 ✅UNICORN🦄 ✅NICHE These trials📚~80 treated. ✔️SAFE. 🔜Time for a phase-2/3. @OncoAlert #CRCSM
Pashtoon Kasi MD, MS tweet media
English
7
32
89
11.8K
Dhan Chand retweetledi
Cancer Discovery
Cancer Discovery@CD_AACR·
From the December issue: Botensilimab, an Fc-enhanced anti-CTLA-4 antibody, Is Effective Against Tumors Poorly Responsive to Conventional Immunotherapy bit.ly/4gqFUKh By @dhanschand and colleagues @Agenus_Bio
Cancer Discovery tweet media
English
2
9
30
3.6K
Dhan Chand
Dhan Chand@dhanschand·
Excited to share our latest research at #SITC2024! Priya Iyer presents AGEN1721: a novel Fc-enhanced bifunctional antibody targeting FAP & TGFβ. Depletes FAP+ CAFs & neutralizes TGFβ to transform immune-excluded tumors. Visit Poster #1355 today! #immunotherapy #cancer"
Houston, TX 🇺🇸 English
1
0
2
184
Dhan Chand
Dhan Chand@dhanschand·
@IdoAmitLab Thank you @IdoAmitLab. Your Nat Cancer 2022 paper on the role of Fc driving myeloid activation was indeed influential in how we interpreted our findings with botensilimab, an Fc-enhanced anti-CTLA-4.
English
1
0
6
147
Dhan Chand retweetledi
Jennifer Buell
Jennifer Buell@jbuell01·
📢 NCI Announces Availability of Botensilimab for Clinical Development Botensilimab is available through the NCI CTEP program in collaboration with Agenus. Strong LOIs for clinical studies are being evaluated. investor.agenusbio.com/news/news-deta…
English
2
3
26
1.8K
Dhan Chand retweetledi
LUNGevity Foundation
LUNGevity Foundation@LUNGevity·
New dual TIGIT & CD96 blocking immunotherapy drug effective in activating anti-cancer immune response in mouse models. Efficacy increased when combined with PD-L1 blocking immunotx. Phase 1/2 trial that includes patients w/ #NSCLC ongoing #AACR24
LUNGevity Foundation tweet mediaLUNGevity Foundation tweet mediaLUNGevity Foundation tweet media
English
0
3
6
4.1K
Dhan Chand
Dhan Chand@dhanschand·
Today at @AACR we demonstrated the power of MiNK's iNKTs to overcome the limitations of immune checkpoint blockade therapy to eliminate MSS colorectal liver metastases. Potential to be a powerful combination partner with Bot/BAL. #AACR24, #Immunotherapy. @MiNK_iNKT @Agenus_Bio.
Dhan Chand tweet media
San Diego, CA 🇺🇸 English
0
1
6
371

Keşfet

@NatureCancer @lab_kok @cityofhope @MyriamChalabi @CancerWorldmag @FilippoPietran4 @OncoAlert @Agenus_Bio